SBIR-STTR Award

Intravesical Chitosan Il-12 Therapy in an Orthotopic Mouse Bladder Cancer Model
Profile last edited on: 10/30/2014

Program
SBIR
Agency
NIH | NCI
Total Award Amount
$225,000
Award Phase
1
Principal Investigator
Wolff Mayer Kirsch
Activity Indicator

Company Information

Scion Biomededical Inc (AKA:Scion Cardio-Vascular Inc~Scion Capital Corporation)

14256 Southwest 119th Avenue
Miami, FL 33186
   (305) 259-8880
   info@scionbiomed.com
   www.scionbiomed.com
Multiple Locations:   
Congressional District:   26
County:   Miami-Dade

Phase I

Phase I year
2014
Phase I Amount
$225,000
This SBIR project brings together the skills and resources of laboratories at Scion Cardio-Vascular Inc. (Scion C-V), Loma Linda University, and North Carolina State University to advance a new signaling molecule treatment for superficial bladder cancer. This treatment delivers the cytokine Interleukin 12 (IL-12) to the bladder wall using Scion C-V's mucoadherent, depyrogenated chitosan (Ch) hydrogel (Ch+IL-12) as the vehicle. Therapeutic effectiveness of the depyrogenated Ch+IL-12 hydrogel will be studied in a relevant mouse bladder cancer model, replicating the pre-clinical studies performed at the National Cancer Institute (NCI). The NCI studies showed remarkable cures of bladder cancer in a mouse model treated with intravesicular Ch+IL- 12. The NCI was preparing to test treatment of superficial bladder cancer with Ch+IL-12 in a controlled clinical trial but cancelled the study because of widespread pyrogen contamination in commercially available 'medical grade' chitosans. Pyrogen contamination is a well recognized problem that limits the applicability of chitosan as an excipient for implantable biomedical applications. There is an urgent need to define versatile alternative, methods that reduce the systemic toxicity of chitosan and IL-12 to improve bladder cancer immunotherapy. We have found that treating chitosan with non-thermal atmospheric nitrogen gas plasma (NtANP) both reduces chitosan endotoxins and may enhance mucoadhesion. As a Phase I study, we will test the hypothesis that our NtANP technology will enable an FDA approved safe and economical Ch+IL-12 delivery vehicle.

Thesaurus Terms:
Advanced Development;Bladder;Blood Vessels;Cancer Immunotherapy;Cancer Model;Chitosan;Clinical Trials;Collaborations;Controlled Clinical Trials;Cytokine;Drug Combinations;Drug Delivery Systems;Efficacy Testing;Elements;Endotoxins;Excipients;Fda Approved;Feasibility Studies;Gases;Goals;Human;Hydrogels;Immune;Immunotherapeutic Agent;Implantation;Improved;Interleukin-12;Intravesical;Laboratories;Legal Patent;Malignant Neoplasm Of Urinary Bladder;Manufacturer Name;Medical;Methods;Morphologic Artifacts;Mouse Model;Mus;National Cancer Institute;Nitrogen;North Carolina;Paracrine;Patients;Pharmaceutical Preparations;Phase;Phase 1 Study;Plasma;Preclinical Study;Process;Property;Public Health Relevance;Pyrogens;Resources;Signaling Molecule;Skills;Small Business Innovation Research Grant;Technology;Testing;Therapeutic Effectiveness;Toxic Effect;Treatment Trial;Tumor;Universities;Work;

Phase II

Phase II year
---
Phase II Amount
---